Glutathione system enhancement for cardiac protection ...

Coronary Artery Bypass Graft Devices Market To Reach $1.38 Billion, Globally By 2032 At 3.7% CAGR: Allied Market Research

The global coronary artery bypass graft devices market is experiencing growth due to factors such as surge in prevalence of cardiovascular diseases, unhealthy diet and modern sedentary lifestyle, and rise in geriatric population. 

PORTLAND, Ore., Oct. 31, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "Coronary Artery Bypass Grafts Device Market by Technology (Off-Pump, On-Pump, and Others), Product (Cardiopulmonary Bypass Machines, Endoscopic Vessel Harvesting Systems, Heart Positioners, Tissue Stabilizer, And Others) and End User (Hospitals, CardiologyCenters, and Others): Global Opportunity Analysis and Industry Forecast, 2023–2032". According to the report, the global coronary artery bypass grafts device market was valued at $0.96 billion in 2022 and is estimated to reach $1.38 billion by 2032, exhibiting a CAGR of 3.7% from 2023 to 2032.

Allied Market Research Logo

Request Sample of the Report on Coronary Artery Bypass Grafts Device Market Forecast 2032- https://www.Alliedmarketresearch.Com/request-sample/198433

Coronary artery bypass graft (CABG) devices are vital instruments utilized in cardiac surgery for addressing coronary artery disease (CAD), a condition characterized by the narrowing or blockage of blood vessels supplying the heart muscle due to the accumulation of plaque. These devices are used to establish new routes for blood circulation, bypassing the diseased or blocked coronary arteries, which in turn enhances blood flow to the heart muscle. This effectively alleviates angina (chest pain) and diminishes the likelihood of a heart attack.

Prime determinants of growth  

The coronary artery bypass graft devices market has experienced significant growth due to alarming increase in the prevalence of cardiovascular diseases worldwide, modern lifestyles, characterized by unhealthy dietary habits and sedentary routines, have become pervasive, contributing to a rise in risk factors such as obesity, hypertension, and diabetes and rise in geriatric population. However, the high cost of coronary artery bypass graft devices restrains the market growth. Moreover, a rise in awareness about heart health will offer remunerative growth opportunities to the market in the upcoming years.

Story continues

Report coverage & details: 

Report Coverage 

Details 

Forecast Period 

2023–2032 

Base Year 

2022

Market Size in 2022 

$0.96 billion 

Market Size in 2032 

$1.38 billion 

CAGR 

3.7 %

No. Of Pages in Report 

294

Segments covered 

Technology, Product, End User, And Region. 

Drivers  

Surge in prevalence of cardiovascular diseases. 

Unhealthy diet and modern sedentary lifestyle. 

Rise in geriatric population 

Opportunities 

Rise in awareness about heart health. 

Restraints 

High cost of coronary artery bypass graft devices. 

Economic Downturn Analysis: Impact of Recession in 2023 on the Coronary Artery Bypass Grafts Device Market

The global recession has created a challenging environment for the coronary artery bypass graft devices market.

The high inflation rate for major key players of coronary artery bypass graft devices market has negatively impacted new product development and research activities.

However, the market for coronary artery bypass graft devices market is expected to recover owing to rise in prevalence of cardiac disorders.

Want to Explore More, Connect to our Analyst- https://www.Alliedmarketresearch.Com/connect-to-analyst/198433

The tissue stabilizer segment to maintain its leadership status throughout the forecast period 

Based on product, the tissue stabilizer segment held the highest market share in 2022, accounting for around one third of the coronary artery bypass graft devices market revenue and is estimated to continue its supremacy throughout the forecast timeframe. This is attributed to high use of tissue stabilizer to ensure the proper stable surgical field. However, the heart positioners segment is expected to register the fastest growth CAGR of 4.5% during the forecasted period owing to high adoption of heart positioners to ensure a clear view of the surgical field.

The hospital segment to maintain its leadership status throughout the forecast period

Based on end user, the hospital segment held the highest market share in 2022, accounting for nearly two-thirds of the global coronary artery bypass graft devices market revenue. This is attributed to the high number of coronary artery bypass graft surgeries performed in the hospitals. The Cardiac centers segment, on the other hand, would cite the fastest growth with 4.8% CAGR from 2023 to 2032, owing to the fact that patients with chronic or stable coronary artery disease often visit cardiology clinics for regular check-ups, medical management, and treatment planning.

The on-pump segment to maintain its leadership status throughout the forecast period 

Based on technology type, the on-pump segment held the highest market share in 2022, accounting for nearly three-fifths of the global coronary artery bypass graft devices market revenue, owing to high adoption of on-pump by surgeons as it provides stable surgical field. However, off pump segment is expected to register the fastest growth in the forecast period owing to the reduced risk of complications during the surgery. Moreover, the off pump CABG segment would cite the fastest growth with 4.2% CAGR during the forecast period, owing to fact the Off-pump CABG is associated with reduced complications such as bleeding, stroke, and kidney dysfunction when compared to on-pump CABG. This makes it an attractive option for patients who want to minimize the risks associated with heart surgery. Furthermore, patients who undergo off-pump CABG often experience shorter hospital stays and faster recovery times.

For Procurement Information- https://www.Alliedmarketresearch.Com/purchase-enquiry/198433

The North America segment to maintain its leadership status throughout the forecast period 

Based on region, the North America segment held the highest market share in 2022, accounting for more than two-fifths of the global coronary artery bypass graft devices market revenue. This is attributed to the rise in geriatric population, strong presence of major key players and well-developed healthcare infrastructure. However, the market across the Asia-Pacific region is expected to witness the fastest growth with 4.5% CAGR from 2023 to 2032. The growth is attributed to the rise in prevalence of coronary heart disease and favorable government initiatives such as national health insurance schemes.

Leading Market Players: - 

The report provides a detailed analysis of these key players in the coronary artery bypass graft devices market. These players have adopted product launch to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.

Comprehensive Healthcare Industry Research Studies:

 Dialysis Market- Global Opportunity Analysis and Industry Forecast, 2022–2032

 Medical Electrodes Market- Global Opportunity Analysis and Industry Forecast, 2022–2032

 Tattoo Removal Market- Global Opportunity Analysis and Industry Forecast, 2022–2032

Neurovascular Devices Market- Global Opportunity Analysis and Industry Forecast, 2022–2032

 Elderly and Disabled Assistive Devices Market- Global Opportunity Analysis and Industry Forecast, 2022–2032

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact

David Correa1209 Orange Street,Corporation Trust Center,Wilmington, New Castle,Delaware 19801 USA.Toll Free: +1-800-792-5285Int'l: +1-503-894-6022UK: +44-845-528-1300Hong Kong: +852-301-84916India (Pune): +91-20-66346060Fax: +1-855-550-5975help@alliedmarketresearch.ComWeb: https://www.Alliedmarketresearch.Com  Follow Us on: LinkedIn Twitter

Logo: https://mma.Prnewswire.Com/media/636519/Allied_Market_Research_Logo.Jpg

Cision

View original content:https://www.Prnewswire.Com/news-releases/coronary-artery-bypass-graft-devices-market-to-reach-1-38-billion-globally-by-2032-at-3-7-cagr-allied-market-research-301972517.Html

SOURCE Allied Market Research

New Study Suggests ECG-AI Can Detect Cardiovascular Disease Risks Sooner

Artificial intelligence (AI) from patient electrocardiograms (ECGs) may be an innovative solution to enhance heart disease risk assessment. Atherosclerotic cardiovascular disease—arteries narrowed or blocked by the accumulation of fatty plaques—is the leading global cause of death and is often driven by coronary artery disease.

New study data published in eClinicalMedicine suggest that ECG-AI can flag some risks years sooner than current risk calculator equations by identifying signs of coronary artery disease, such as calcification and blockages, as well as evidence of a prior heart attack.

Many people may have coronary artery disease and not be aware of it. Unfortunately, the first sign of the disease could be sudden death or a major heart attack. Clinician tools, such as the pooled cohort equation, help determine a patient's 10-year risk for heart attacks and strokes. The tools guide shared decisions about the timing of therapies, but these tools have limitations.

ECG is a widely available test that measures the heart's electrical activity, and AI can be trained to identify and detect hidden patterns of disease from those electrical signals.

The ECG-AI to predict coronary artery disease was developed at Mayo Clinic and Anumana using the retrospective analysis of electronic health data of over 7 million patients across the U.S. Three separate ECG-AI models were trained, one each to detect coronary artery calcium, coronary artery blockage and segments of the heart's left ventricle not moving well—a sign of a prior heart attack.

"Used together, the three independent ECG-AI models predicted which patients had a high risk of hidden coronary artery disease, and therefore a high risk of having a heart attack. This is important information to guide our conversations with patients at the point of care, especially since the AI was useful in calculating these risks for as short as three years," says Francisco Lopez-Jimenez, M.D., a cardiologist at Mayo Clinic and senior author of the paper.

"Used alone, the pooled cohort equation estimates the 10-year risk of developing cardiovascular disease. The addition of ECG-AI to see hidden risks sooner has the potential to save more lives. This model may also help identify people who do not know they have coronary disease who may benefit from lifesaving therapies."

More information: Samir Awasthi et al, Identification and risk stratification of coronary disease by artificial intelligence-enabled ECG, eClinicalMedicine (2023). DOI: 10.1016/j.Eclinm.2023.102259

Citation: New study suggests ECG-AI can detect cardiovascular disease risks sooner (2023, October 25) retrieved 31 October 2023 from https://medicalxpress.Com/news/2023-10-ecg-ai-cardiovascular-disease-sooner.Html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Study Compares Two Widely Used Statins For Treating Patients With Coronary Artery Disease

Two widely used statins, rosuvastatin and atorvastatin, are equally effective at preventing heart attacks, strokes and death in people with coronary artery disease. But while rosuvastatin treatment is associated with lower cholesterol levels, it also carries a higher risk of developing type 2 diabetes than atorvastatin, finds a study published by The BMJ today.

Lowering "bad" (LDL) cholesterol levels with statins is recommended for people with coronary artery disease - a condition where the blood vessels supplying the heart are narrowed or blocked.

But few trials have directly compared the long term clinical effects of the two most potent statins-;rosuvastatin and atorvastatin-;in people with coronary artery disease.

To address this, researchers in Korea analysed the results of the LODESTAR clinical trial, involving 4,400 adults (average age 65 years; 28% women) with coronary artery disease at 12 hospitals in South Korea.

At the start of the trial, medical history and lifestyle information was recorded and participants were randomly assigned to receive either daily rosuvastatin or atorvastatin for three years from September 2016 to November 2019.

The researchers then examined differences between the two groups in terms of deaths from any cause and rates of heart attacks, strokes, and coronary revascularisation (procedures to restore blood flow to parts of the heart).

Several other safety outcomes, including development of type 2 diabetes, hospital admissions due to heart failure, major blood clots, and cataract surgery were also assessed.

In all, 4,341 of the 4,400 participants (98.7%) completed the trial.

The researchers found no discernible differences between the two groups for all cause death (2.6% in the rosuvastatin group v 2.3% in the atorvastatin group), heart attack (1.5% v 1.2%), stroke (1.1% v 0.9%) or any revascularisation (5.3% v 5.2%).

The average LDL cholesterol level during the study period was lower in the rosuvastatin group than atorvastatin group (1.8 v 1.9 mmol/L).

The rosuvastatin group had a higher rate of developing type 2 diabetes requiring medication (7.2% v 5.3%) and cataract surgery (2.5% v 1.5%), but other safety outcomes did not differ between the two groups.

The researchers acknowledge several study limitations including the fact that only Asian participants were included in this trial, and the three-year study period may have been relatively short to find longer term effects of two statin types.

As such, they say their findings "should be interpreted with caution, and further dedicated investigation with longer follow-up is warranted."

However, they conclude: "In people with coronary artery disease, rosuvastatin and atorvastatin showed comparable efficacy in terms of a composite of all cause death, myocardial infarction, stroke, or any coronary revascularisation within three years."

They add: "Rosuvastatin was associated with lower LDL cholesterol levels, but it incurred a higher risk of new onset diabetes mellitus requiring antidiabetics and cataract surgery than atorvastatin."

Source:

Journal reference:

Lee, Y.-J., et al. (2023). Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial. BMJ. Doi.Org/10.1136/bmj-2023-075837

---